Milestone Scientific Inc. (MLSS)

Milestone Scientific's stock price has fluctuated over the past six months. Key events include the expansion of its CompuFlo® medical business, a $2.15 million private placement, and the report of financial results for the fourth quarter and full year 2025, missing top-line estimates. Strategic initiatives under new leadership were announced to enhance growth and operational efficiency.

The provided information does not explicitly detail any specific demand seasonality for Milestone Scientific, Inc.'s products and services. However, the company operates in the medical and dental device industries, which may experience demand fluctuations related to factors such as healthcare budget cycles, elective procedure scheduling, or academic calendars for training and adoption. The company's projected sales growth for 2025 and 2026 is supported by enhanced coverage of the CompuFlo procedure by Medicare Administrative Contractors and a strategic shift towards direct online sales in the dental sector.

Milestone Scientific, Inc. is a biomedical technology company specializing in innovative injection technologies for medical and dental applications. Their core technology is Dynamic Pressure Sensing (DPS) Technology, which enhances the safety and precision of injections. Major products include The Wand®/STA Single Tooth Anesthesia (STA) System, CompuFlo® Epidural System, and CompuDent® System. The company is also developing a cosmetic injection device for botulinum toxin delivery.

Milestone Scientific distributes its technologies through direct sales and partnerships in North America, Europe, Latin America, and parts of Asia. Its dental devices are sold in the United States, U.S. territories, Canada, and in 60 other countries. The CompuFlo® medical business is expanding its advisor program and clinical engagement across key Medicare Administrative Contractor (MAC) jurisdictions in the US. Export sales represented approximately 45% of 2025 revenue, indicating significant international penetration across roughly 37 countries.

Milestone Scientific's brand reputation is built on enhancing patient comfort and improving clinical outcomes through its computer-controlled injection technologies. The company's systems are supported by clinical research and patents. Milestone Scientific scored higher than 25% of companies evaluated by MarketBeat and ranked 745th out of 857 stocks in the medical sector. One analyst has a "Buy" rating for MLSS stock with a 12-month price target of $1.00.

Milestone Scientific Inc. has 31 institutional owners and shareholders holding a total of 4,528,557 shares. Major institutional shareholders include Vanguard Group Inc, Geode Capital Management, Llc, Citadel Advisors Llc, State Street Corp, Mariner, LLC, Northern Trust Corp, LPL Financial LLC, Pensionmark Financial Group, Llc, Carnegie Capital Asset Management, LLC, and Bridgeway Capital Management Inc. Institutional ownership is approximately 16.1%, while individual ownership stands at about 10.88%. Insiders hold 12.51% of the stock.